T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

DISEASE CHARACTERISTICS:

* Diagnosis of 1 of the following hematologic malignancies:

  * Acute myeloid leukemia (AML), meeting 1 of the following criteria:

    * In first complete remission (CR1), meeting 1 of the following criteria:

      * Adverse cytogenetics with minimal residual disease detectable by flow cytometry, cytogenetic analysis, fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR), defined as 1 of the following:

        * Complex karyotype \[≥ 3 abnormalities\]
        * inv(3) or t(3;3)
        * t(6;9)
        * t(6;11)
        * Monosomy 7
        * Trisomy 8, alone or with an abnormality other than t(8;21), t(9;11), inv(16), or t(16;16)
        * t(11;19) (q23;p13.1)
      * Failed to achieve CR after primary induction chemotherapy
      * Secondary AML
    * In second or subsequent remission (CR2 or greater)
  * Acute lymphoblastic leukemia, meeting 1 of the following criteria:

    * In CR1, meeting 1 of the following criteria:

      * Adverse cytogenetics with minimal residual disease detectable by flow cytometry, cytogenetic analysis, FISH, or PCR, defined as the following:

        * Translocations involving 11q23, t(9;22), or bcr-abl rearrangement
      * Failed to achieve CR after primary induction chemotherapy
    * In CR2, if CR1 was \< 12 months
    * In CR3 or greater
  * Myelodysplastic syndromes (MDS)

    * INT-2 or high-risk by International Prognostic Scoring System
    * No MDS with Fanconi anemia
  * Chronic myelogenous leukemia (CML), meeting 1 of the following criteria:

    * Accelerated phase with treatment failure after imatinib mesylate
    * Blast phase
  * Myeloproliferative disorders, meeting 1 of the following criteria:

    * Agnogenic myeloid metaplasia with adverse-risk features, meeting at least 2 of the following criteria:

      * Hemoglobin \< 10 g/dL or \> 10g/dL if transfusion-dependent
      * WBC \< 4,000/mm\^3 OR \> 30,000/mm\^3 OR requires cytoreductive therapy to maintain WBC \< 30,000/mm\^3
      * Abnormal cytogenetics, including +8, 12p-
    * Polycythemia vera or essential thrombocythemia in transformation to secondary AML
  * Myelodysplastic/myeloproliferative disease

    * Chronic myelomonocytic leukemia
  * Hodgkin's lymphoma or non-Hodgkin's lymphoma

    * Refractory lymphoma with progressive disease during combination chemotherapy
    * Relapse after OR ineligible for autologous stem cell transplantation (SCT)
  * Chronic lymphocytic leukemia

    * Treatment failure\* after fludarabine, chlorambucil, and at least 1 other salvage regimen
  * Prolymphocytic leukemia (PLL), meeting 1 of the following criteria:

    * T-PLL

      * Treatment failure\* after alemtuzumab and at least 1 other regimen
    * B-PLL

      * Treatment failure\* after fludarabine and at least 1 other salvage regimen
  * Multiple myeloma, meeting 1 of the following criteria:

    * Relapse after autologous SCT
    * Plasma cell leukemia
    * Adverse cytogenetics, defined as 1 of the following:

      * del(13q) = 11q translocation NOTE: \*Treatment failure is defined as relapse within 6 months OR failure to achieve remission
* Less than 10% blasts in bone marrow and no circulating blasts in peripheral blood for the following diagnoses:

  * Primary or secondary leukemia
  * Refractory anemia with excess blasts
  * CML
  * Other eligible diagnosis in transformation to acute leukemia
* Expected survival of approximately 1 year or less with conventional therapy
* No active CNS involvement by malignancy\*

  * Prior CNS involvement with no current evidence of CNS malignancy allowed NOTE: \*Active CNS malignancy is defined by lymphoma: tumor mass on CT scan or leptomeningeal disease OR leukemia: blasts present on cerebrospinal fluid cytospin
* Availability of a donor who is a sibling, parent, or offspring who shares 1 full haplotype (HLA-A, -B, or -DR)

  * Recipient and donor must have at least a 2-antigen disparity in either the host-versus-graft or graft-versus-host direction
  * Parent or offspring donor who is mismatched for a single HLA antigen (i.e., 5/6 HLA) is allowed
  * No sibling donor who is 6/6 HLA-matched OR mismatched for a single HLA antigen (i.e., 5/6 HLA)
  * No unrelated donor identified in a prior or current National Marrow Donor Program registry search

PATIENT CHARACTERISTICS:

Age

* 18 to 55

Performance status

* ECOG 0-2 OR
* Karnofsky 60-100%

Life expectancy

* At least 3 months

Hematopoietic

* See Disease Characteristics
* Absolute neutrophil count ≥ 1,000/mm\^3\*
* Platelet count ≥ 20,0000/mm\^3\* (without transfusion) NOTE: \*Lower values may be accepted at the discretion of the principal investigator or study chairperson if due to bone marrow involvement by malignancy

Hepatic

* ALT and AST ≤ 2.5 times upper limit of normal (ULN)\*
* Bilirubin ≤ 2.5 times ULN\*
* Unconjugated hyperbilirubinemia consistent with Gilbert's syndrome allowed
* No chronic active hepatitis B infection

  * Hepatitis B core antibody positive allowed provided patient is surface antigen negative and has no evidence of active infection
* No hepatitis C viral infection

  * Seronegative for anti-hepatitis C antibody and detectable hepatitis C viral RNA by reverse transcriptase-polymerase chain reaction assay NOTE: \*Higher levels may be accepted at the discretion of the principle investigator or study chairperson if such elevations are due to liver involvement by malignancy

Renal

* Creatinine ≤ 1.5 mg/dL OR
* Creatinine clearance ≥ 50 mL/min

Cardiovascular

* LVEF ≥ 45%

Pulmonary

* DLCO ≥ 50% of expected value (corrected for blood hemoglobin level and alveolar volume)

Other

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 1 year after study participation
* HIV negative
* No active infection not responding to antimicrobial therapy
* No psychiatric disorder that would preclude study compliance or informed consent

PRIOR CONCURRENT THERAPY:

Biologic therapy

* See Disease Characteristics
* At least 2 weeks since prior monoclonal antibody therapy

Chemotherapy

* See Disease Characteristics
* At least 2 weeks since prior systemic chemotherapy

Endocrine therapy

* Not specified

Radiotherapy

* Not specified

Surgery

* Not specified

Other

* Recovered from all prior therapy
* No administration of tyrosine kinase (TK) inhibitors, including imatinib mesylate and dasatinib, during the conditioning regimen; TK inhibitor administration may resume 28 days after transplantation